A randomized, open-label, phase 1 study to evaluate the effect of food on tivantinib (ARQ 197) pharmacokinetics

被引：0

作者：

Zahir, Hamim ^{[1
]}

Oguma, Toshihiro ^{[1
]}

Currie, Alexander ^{[2
]}

Lee, Frank ^{[3
,4
]}

Walker, Joseph ^{[1
]}

Tokui, Taro

机构：

[1] Daiichi Sankyo Pharma Dev, Edison, NJ USA

[2] Daiichi Sankyo Europe GmbH, Munich, Germany

[3] Celerion, Neptune, NJ USA

[4] Daiichi Sankyo Pharma Dev, Tokyo, Japan

来源：

CANCER RESEARCH | 2012年 / 72卷

关键词：

D O I：

10.1158/1538-7445.AM2012-755

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

755

引用

页数：1

共 50 条

[41] An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin
Alberto Gabizon
Rut Isacson
Ora Rosengarten
Dina Tzemach
Hilary Shmeeda
Rama Sapir
Cancer Chemotherapy and Pharmacology, 2008, 61 : 695 - 702
[42] A Phase 4, Multicenter, Randomized, Open-Label Study to Evaluate the Effect of Belimumab on Vaccine Responses in Patients with Systemic Lupus Erythematosus
Chatham, Winn
Chadha, Aneureka
Fettiplace, James
Kleoudis, Christi
Bass, Damon
Roth, David
Gordon, David
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[43] An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin
Gabizon, Alberto
Isacson, Rut
Rosengarten, Ora
Tzemach, Dina
Shmeeda, Hilary
Sapir, Rama
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (04) : 695 - 702
[44] A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation
van Rossem, Koen
Lowe, Jenny A.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2013, 5 : 23 - 31
[45] Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects
Tachibana, Masaya
Matsuki, Shunji
Maekawa, Yutaro
Kuroda, Kana
Shimizu, Takako
Tsutsumi, Junko
Ishizuka, Hitoshi
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (11): : 2153 - 2162
[46] Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
Sara M. Tolaney
Sally Tan
Hao Guo
William Barry
Eliezer Van Allen
Nikhil Wagle
Jane Brock
Katherine Larrabee
Cloud Paweletz
Elena Ivanova
Pasi Janne
Beth Overmoyer
John J. Wright
Geoffrey I. Shapiro
Eric P. Winer
Ian E. Krop
Investigational New Drugs, 2015, 33 : 1108 - 1114
[47] A phase 1 randomized open-label clinical study to evaluate the safety CrossMark and tolerability of a novel recombinant hepatitis E vaccine
Cao, Yu-Feng
Tao, Hong
Hu, Yue-Mei
Shi, Cheng-Bo
Wu, Xing
Liang, Qi
Chi, Chun-Ping
Li, Li
Liang, Zheng-Lun
Meng, Ji-Hong
Zhu, Feng-Cai
Liu, Zhao-Hui
Wang, Xin-Ping
VACCINE, 2017, 35 (37) : 5073 - 5080
[48] A Phase 1, Open-Label, Randomized, Two-Part Study in Healthy Adult Volunteers to Evaluate the Bioavailability of the Maribavir Powder for Oral Suspension, as Well as Food Effect and Impact of Rabeprazole
Campagne, Olivia
Ilic, Katarina
Gabriel, Andre
Sueda, Katsuhiko
Ye, Ran
Zhang, Fangqiu
Xu, Peixin
Ko, Hnin Hnin
Sun, Kefeng
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2025, 14 (02): : 133 - 143
[49] SECOND LINE THERAPY IN HEPATOCELLULAR CARCINOMA (HCC): A RANDOMIZED CONTROLLED PHASE 2 TRIAL (RCT) WITH TIVANTINIB (ARQ 197)
Porta, Camillo
Borbath, Ivan
Rimassa, Lorenza
Daniele, Bruno
Salvagni, Stefania
Van Laethem, Jean Luc
Van Vlieberghe, Hans
Trojan, Joerg
Kolligs, Frank
Gasbarrini, Antonio
Weiss, Alan
Lencioni, Monica
Abbadessa, Giovanni
Schwartz, Brian
Santoro, Armando
ANNALS OF ONCOLOGY, 2012, 23 : 8 - 8
[50] Effect of Food on the Pharmacokinetics of Clozapine Orally Disintegrating Tablet 12.5 mgA Randomized,Open-Label,Crossover Study in Healthy Male Subjects
Anthony R. DiSanto
Gil Golden
Clinical Drug Investigation, 2009, 29 : 539 - 549

← 1 2 3 4 5 →